

FOR IMMEDIATE RELEASE

RIBOPRO Secures €1.9M Convertible Loan Agreement, Catalyzing Advances in mRNA Technology and Paving the Way for Series A Financing

Oss, the Netherlands, 10th of January 2024 — RIBOPRO, a leading biotechnology company dedicated to supporting biotech and biopharma in the co-creation of innovative mRNA medicines based on proprietary mRNA technologies and high-quality mRNA/LNP manufacturing, proudly announces the successful completion of a €1.9 million Convertible Loan Agreement (CLA) that marks a significant milestone in its growth trajectory.

The CLA is a testament to the confidence and support from existing investors Vlasroot, BOM, the Fredriks family, and supervisory board member Wietse Mulder, representing EchiumBio Holding BV, who all share RIBOPRO's vision for revolutionizing healthcare through mRNA innovations. The funding obtained through this agreement will propel several Research and Development (R&D) initiatives forward to specific value inflection points and further streamline production processes to position RIBOPRO for a successful Series A financing.

Sander van Asbeck, CEO of RIBOPRO, expressed enthusiasm about the recent development, stating: "With this infusion of capital, we specifically aim to deliver proof of concept for our next generation LNP technology and advance the development of our state-of-the-art mRNA/LNP manufacturing machine, bringing us closer to becoming the go-to provider of mRNA technologies and high quality (GMP) manufacturing. The anticipated breakthrough in mRNA/LNP performance will benefit the hundreds of existing customers, as well as accelerate the acquisition of novel partnerships. We are grateful for the trust and support from our investors, enabling us to grow further into a mature and profitable company and deliver on our mission."

Roel Elshout, supervisory board member at RIBOPRO and representing Vlasroot: expressed excitement about the investment, stating: "We believe in RIBOPRO's ability to drive meaningful change in the biotech landscape. The innovative mRNA-centric solutions under development by RIBOPRO aligns with our commitment to supporting groundbreaking technologies that have the potential to transform the future of healthcare."

Wietse Mulder, supervisory board member at RIBOPRO and representing EchiumBio, shared their perspective, saying: "I am thrilled to be part of RIBOPRO's journey. The completion of the Convertible Loan Agreement signifies a strong endorsement of the company's vision and capabilities. We look forward to witnessing the impactful contributions RIBOPRO will make in advancing mRNA research and therapy development."



For media inquiries, please contact:

Silvy van Tuijl

Chief of Staff

RIBOPRO

vantuijl@ribopro.eu

085 060 6762

About RIBOPRO:

RIBOPRO is a pioneering biotechnology company focused on developing advanced mRNA technologies for the development of radically better medicines. Committed to scientific excellence, RIBOPRO aims to drive innovation in the field of mRNA-based drug development and mRNA manufacturing, with a vision of enabling biotech and biopharma companies around the world to create transformative solutions for unmet medical needs via a co-creation model, at scale. For more information, visit www.ribopro.eu.